KRN23 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
238Vitamin D-resistant rickets13

238. Vitamin D-resistant rickets


Clinical trials : 28 Drugs : 20 - (DrugBank : 9) / Drug target genes : 3 - Drug target pathways : 16
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05357573
(ClinicalTrials.gov)
August 11, 202227/4/2022Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIOAn Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)Tumor-Induced Osteomalacia (TIO)Drug: KRN23Kyowa Kirin Co., Ltd.NULLRecruiting18 YearsN/AAll10Phase 4China
2NCT04842032
(ClinicalTrials.gov)
October 5, 202130/3/2021Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHAn Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)X-linked Hypophosphatemia (XLH)Drug: KRN23Kyowa Kirin Co., Ltd.NULLRecruiting1 Year12 YearsAll28Phase 4China
3NCT04842019
(ClinicalTrials.gov)
August 30, 202130/3/2021Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHAn Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaX-linked Hypophosphatemia (XLH)Drug: KRN23Kyowa Kirin Co., Ltd.NULLRecruiting18 Years65 YearsAll18Phase 4China
4NCT04320316
(ClinicalTrials.gov)
July 31, 202011/3/2020A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome (ENS) and Associated Hypophosphatemic RicketsEpidermal Nevus SyndromeDrug: Crysvita (burosumab-twza) TreatmentUniversity of Alabama at BirminghamUltragenyx Pharmaceutical IncCompleted6 MonthsN/AMale1Phase 4United States
5NCT03581591
(ClinicalTrials.gov)
January 31, 201827/10/2017Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic RicketsAn Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic RicketsHypophosphatemia;Hypophosphatemic Rickets;Pain, ChronicBiological: BurosumabRedwood Dermatology SciencesUltragenyx Pharmaceutical IncCompletedN/A18 YearsFemale1Phase 3United States
6JPRN-JapicCTI-205284
09/1/201811/05/2020A Study of KRN23 in Adult and Pediatric Patients with X-linked Hypophosphatemic Rickets/OsteomalaciaPhase 3 Long-term Extension Study of KRN23 in Patients with X-linked Hypophosphatemic Rickets/Osteomalacia Adult or pediatric XLHIntervention name : burosumab
INN of the intervention : KRN23
Dosage And administration of the intervention : repeated SC administration
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Kyowa Kirin Co., Ltd.NULLcompleteBOTH27Phase 3Japan, Asia except Japan
7NCT04308096
(ClinicalTrials.gov)
January 9, 201826/2/2020A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaA Phase 3 Long-term Extension Study of KRN23 in Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched From the Phase 3 Long-term Extension StudyXLHDrug: KRN23Kyowa Kirin Co., Ltd.NULLCompletedN/AN/AAll27Phase 3Japan;Korea, Republic of
8JPRN-JapicCTI-173614
31/7/201715/06/2017A Study of KRN23 in Pediatric Patients with X-linked Hypophosphatemic Rickets/OsteomalaciaA Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients with X-linked Hypophosphatemic Rickets/Osteomalacia X-linked Hypophosphatemic Rickets/OsteomalaciaIntervention name : KRN23
INN of the intervention : burosumab
Dosage And administration of the intervention : repeated SC administration
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Kyowa Kirin Co., Ltd.NULLcomplete112BOTH10Phase 3Japan
9NCT03233126
(ClinicalTrials.gov)
July 6, 201711/7/2017A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaA Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 TrialX-linked Hypophosphatemic Rickets/OsteomalaciaDrug: KRN23Kyowa Kirin Co., Ltd.NULLCompleted1 Year12 YearsAll16Phase 3Japan
10NCT02722798
(ClinicalTrials.gov)
April 20167/3/2016A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus SyndromeA Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome and a Post-marketing Study of KRN23 Switched From the Phase 2 TrialTumor-Induced Osteomalacia or Epidermal Nevus SyndromeDrug: KRN23Kyowa Kirin Co., Ltd.NULLCompleted18 YearsN/AAll14Phase 2Japan;Korea, Republic of
11JPRN-JapicCTI-163191
23/4/201508/03/2016A Phase 2 Open-Label Trial of KRN23A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Tumor-Induced Osteomalacia or Epidermal Nevus SyndromeIntervention name : KRN23
INN of the intervention : burosumab
Dosage And administration of the intervention : repeated SC administration, intraindividual dose adjustment
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Kyowa Kirin Co., Ltd.NULLcomplete18BOTH6Phase 2Japan, Asia except Japan
12NCT02304367
(ClinicalTrials.gov)
March 24, 201524/11/2014Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated OsteomalaciaTumor Induced Osteomalacia (TIO);Epidermal Nevus Syndrome (ENS)Biological: BurosumabUltragenyx Pharmaceutical IncNULLActive, not recruiting18 YearsN/AAll17Phase 2United States
13NCT02181764
(ClinicalTrials.gov)
July 20142/7/2014A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/OsteomalaciaA Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.X-linked Hypophosphatemic Rickets/OsteomalaciaDrug: KRN23Kyowa Hakko Kirin Co., LtdNULLCompleted18 YearsN/AAll15Phase 1Japan;Korea, Republic of